OpenEvidence Reshapes Healthcare with AI, Secures $210M Funding
July 22, 2025, 3:32 pm
OpenEvidence secured $210M in Series B funding, valuing the leading medical AI platform at $3.5 billion. It simultaneously launched DeepConsult, a revolutionary, free AI agent for all verified U.S. physicians. This platform combats clinician information overload. It delivers real-time, evidence-based answers and comprehensive, AI-driven research reports. OpenEvidence aids high-stakes clinical decisions at the point of care. Its system is HIPAA-compliant. The company uses strategic partnerships with top medical journals like JAMA and NEJM. Over 40% of U.S. doctors use it daily. It supports 8.5 million clinical consultations monthly. This marks a 2,000%+ year-over-year growth. OpenEvidence transforms medical knowledge access. It enhances patient outcomes and reduces physician burnout. AI now supports frontline healthcare like never before.
A major shift impacts U.S. healthcare. OpenEvidence, a leader in medical AI, announced monumental growth. It secured $210 million in Series B funding. This investment boosts its valuation to $3.5 billion. The company redefines how clinicians access vital medical knowledge. It leverages advanced artificial intelligence.
Healthcare professionals face immense pressure. Medical research expands rapidly. Information overload is a critical problem. Clinicians struggle to keep pace. Traditional databases are slow. They require extensive manual searches. This pulls physicians away from patients. It delays critical decisions.
OpenEvidence provides a powerful solution. Its platform empowers physicians. They search once. They find science in seconds. This saves precious time. It enhances decision-making. The system is HIPAA-compliant. It integrates seamlessly into workflow.
Strategic content partnerships are key. OpenEvidence collaborates with leading institutions. This includes the American Medical Association (JAMA). It partners with The New England Journal of Medicine. These agreements ensure access to trusted, peer-reviewed content. Clinicians receive accurate, referenced answers. This builds confidence in every decision.
The core product offers speed. It delivers answers in 5-10 seconds. This is crucial for urgent situations. Physicians get immediate, evidence-based insights. This improves patient care. It reduces the lag between new evidence and bedside application.
A groundbreaking new tool has arrived. OpenEvidence unveiled DeepConsult™. This is the first AI agent built specifically for physicians. DeepConsult offers a personal research team. These are PhD-level, medically-specialized AI agents. They operate autonomously.
DeepConsult handles complex medical queries. It analyzes hundreds of studies in parallel. It uses advanced reasoning models. This uncovers novel connections. It reveals insights a human might miss. The result is a comprehensive, interdisciplinary synthesis. Such reports once took months to produce.
DeepConsult provides in-depth research reports. This differs from the quick search. Physicians use it for complex questions. They utilize it during breaks. The service requires significant computing power. Its cost is substantial. Yet, OpenEvidence offers DeepConsult for free. It is available to all verified U.S. clinicians. This reinforces its mission to support frontline healthcare.
OpenEvidence adoption rates are staggering. The platform operates across 10,000+ hospitals. It serves medical centers nationwide. Over 40% of U.S. physicians use it daily. New clinician registrations exceed 65,000 monthly. This represents rapid expansion.
Growth figures demonstrate impact. In July 2024, OpenEvidence supported 358,000 physician consultations. One year later, this number soared. It now handles 8.5 million consultations monthly. This marks over 2,000% year-over-year growth. Millions of Americans benefit directly. Their doctors make better, faster decisions.
The Series B funding round reflects strong investor confidence. Google Ventures co-led the round. Kleiner Perkins also co-led the investment. Sequoia Capital provided follow-on investment. Additional participants included Coatue, Conviction, and Thrive. Total funding for OpenEvidence now exceeds $300 million.
The company was founded by visionary leaders. Daniel Nadler and Zachary Ziegler are MIT- and Harvard-trained PhDs. Nadler is known for founding Kensho. S&P Global acquired Kensho for $700 million. Nadler also made the TIME100 Health list in 2025. This recognizes his global health influence.
The new capital fuels future expansion. OpenEvidence will strengthen content partnerships. This enhances its vast library of medical knowledge. The goal remains clear: empower every physician. Provide them with cutting-edge AI tools.
OpenEvidence addresses critical healthcare challenges. Clinician burnout is rampant. A physician shortage looms. AI offers a powerful solution. It acts as a tireless copilot. It supports doctors. It benefits patients. The future of evidence-based medicine is here. It is driven by AI. It is led by OpenEvidence.
A major shift impacts U.S. healthcare. OpenEvidence, a leader in medical AI, announced monumental growth. It secured $210 million in Series B funding. This investment boosts its valuation to $3.5 billion. The company redefines how clinicians access vital medical knowledge. It leverages advanced artificial intelligence.
Healthcare professionals face immense pressure. Medical research expands rapidly. Information overload is a critical problem. Clinicians struggle to keep pace. Traditional databases are slow. They require extensive manual searches. This pulls physicians away from patients. It delays critical decisions.
OpenEvidence provides a powerful solution. Its platform empowers physicians. They search once. They find science in seconds. This saves precious time. It enhances decision-making. The system is HIPAA-compliant. It integrates seamlessly into workflow.
Strategic content partnerships are key. OpenEvidence collaborates with leading institutions. This includes the American Medical Association (JAMA). It partners with The New England Journal of Medicine. These agreements ensure access to trusted, peer-reviewed content. Clinicians receive accurate, referenced answers. This builds confidence in every decision.
The core product offers speed. It delivers answers in 5-10 seconds. This is crucial for urgent situations. Physicians get immediate, evidence-based insights. This improves patient care. It reduces the lag between new evidence and bedside application.
A groundbreaking new tool has arrived. OpenEvidence unveiled DeepConsult™. This is the first AI agent built specifically for physicians. DeepConsult offers a personal research team. These are PhD-level, medically-specialized AI agents. They operate autonomously.
DeepConsult handles complex medical queries. It analyzes hundreds of studies in parallel. It uses advanced reasoning models. This uncovers novel connections. It reveals insights a human might miss. The result is a comprehensive, interdisciplinary synthesis. Such reports once took months to produce.
DeepConsult provides in-depth research reports. This differs from the quick search. Physicians use it for complex questions. They utilize it during breaks. The service requires significant computing power. Its cost is substantial. Yet, OpenEvidence offers DeepConsult for free. It is available to all verified U.S. clinicians. This reinforces its mission to support frontline healthcare.
OpenEvidence adoption rates are staggering. The platform operates across 10,000+ hospitals. It serves medical centers nationwide. Over 40% of U.S. physicians use it daily. New clinician registrations exceed 65,000 monthly. This represents rapid expansion.
Growth figures demonstrate impact. In July 2024, OpenEvidence supported 358,000 physician consultations. One year later, this number soared. It now handles 8.5 million consultations monthly. This marks over 2,000% year-over-year growth. Millions of Americans benefit directly. Their doctors make better, faster decisions.
The Series B funding round reflects strong investor confidence. Google Ventures co-led the round. Kleiner Perkins also co-led the investment. Sequoia Capital provided follow-on investment. Additional participants included Coatue, Conviction, and Thrive. Total funding for OpenEvidence now exceeds $300 million.
The company was founded by visionary leaders. Daniel Nadler and Zachary Ziegler are MIT- and Harvard-trained PhDs. Nadler is known for founding Kensho. S&P Global acquired Kensho for $700 million. Nadler also made the TIME100 Health list in 2025. This recognizes his global health influence.
The new capital fuels future expansion. OpenEvidence will strengthen content partnerships. This enhances its vast library of medical knowledge. The goal remains clear: empower every physician. Provide them with cutting-edge AI tools.
OpenEvidence addresses critical healthcare challenges. Clinician burnout is rampant. A physician shortage looms. AI offers a powerful solution. It acts as a tireless copilot. It supports doctors. It benefits patients. The future of evidence-based medicine is here. It is driven by AI. It is led by OpenEvidence.